EUVIMEDEUVIMED entdecken
Crossref

Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Masanao Shinohara, Hayato Yamamoto, Yohei Kawashima, Yuya Sekine, Shintaro Narita iD, Shin Kobayashi, Noriyuki Abe, Hirotake Kodama iD, Naoki Fujita iD, Teppei Okamoto iD, Kazuyuki Numakura, Satoshi Sato und 3 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Masanao Shinohara und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Premedication, Carcinoma, Transitional Cell, Dexamethasone, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Enfortumab vedotin (EV) is the standard treatment for locally advanced or metastatic urothelial carcinoma (la/mUC), though skin toxicities are problematic. We evaluated whether prophylactic corticosteroid premedication is associated with reduced toxicity and survival outcomes.

Methods

We retrospectively analyzed 157 patients with la/mUC receiving EV monotherapy, stratified by prophylactic intravenous dexamethasone (6.6 mg) premedication (pre‐EV steroid, n = 20) or not (no pre‐EV steroid, n = 137). Endpoints included the incidence of EV‐related adverse events (AEs), objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS). Inverse probability of treatment weighting (IPTW) was used to adjust for baseline imbalances.

Results

Corticosteroid premedication was associated with a significantly lower incidence of skin AEs (10% vs. 62.7%, p < 0.001) and a reduced number of cumulative AEs (median 1 vs. 2, p = 0.018). The ORR were comparable. However, patients with steroid premedication showed inferior OS compared to those without (median OS 10.3 vs. 17.4 months, p = 0.008), while PFS showed no significant difference. Multivariable analysis confirmed corticosteroid premedication as an independent predictor of reduced skin AEs (OR 0.08, p = 0.001); however, it was associated with worse OS (HR 1.91, p = 0.048), with no significant impact on PFS. In the IPTW‐adjusted analysis, corticosteroid premedication remained significantly associated with worse OS.

Conclusions

Corticosteroid premedication reduces skin toxicities during EV monotherapy, but its impact on survival remains uncertain and requires validation in larger studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PremedicationCarcinoma, Transitional CellDexamethasoneUrinary Bladder NeoplasmsDrug EruptionsAntineoplastic Agents, ImmunologicalHumansFemaleRetrospective StudiesMaleAgedMiddle AgedAged, 80 and overProgression-Free SurvivalAdministration, Intravenous

Stichwörter der Autor:innen

adverse eventscorticosteroid premedicationcutaneous toxicityenfortumab vedotinurothelial carcinoma

Substanzen

DexamethasoneAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Urology, Ageo Central General Hospital, Ageo, Japan.
  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, Asahikawa Medical University, Asahikawa, Japan.
  • Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

ORCID-Profile: Shintaro Narita, Hirotake Kodama, Naoki Fujita, Teppei Okamoto, Shingo Hatakeyama

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Shinohara, M., Yamamoto, H., Kawashima, Y., Sekine, Y., Narita, S., Kobayashi, S., Abe, N., Kodama, H., Fujita, N., Okamoto, T., Numakura, K., Sato, S., Habuchi, T., Ohyama, C., & Hatakeyama, S. (2026). Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.70425

Vancouver

Shinohara M, Yamamoto H, Kawashima Y, Sekine Y, Narita S, Kobayashi S, et al. Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. International Journal of Urology. 2026. doi:10.1111/iju.70425

BibTeX
@article{Shinohara2026,
  author = {Shinohara, Masanao and Yamamoto, Hayato and Kawashima, Yohei and Sekine, Yuya and Narita, Shintaro and Kobayashi, Shin and Abe, Noriyuki and Kodama, Hirotake and Fujita, Naoki and Okamoto, Teppei and Numakura, Kazuyuki and Sato, Satoshi and Habuchi, Tomonori and Ohyama, Chikara and Hatakeyama, Shingo},
  title = {Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70425}
}
Kostenlos starten →